BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Molenberghs G, Burzykowski T, Alonso A, Assam P, Tilahun A, Buyse M. A unified framework for the evaluation of surrogate endpoints in mental-health clinical trials. Stat Methods Med Res 2010;19:205-36. [PMID: 19608602 DOI: 10.1177/0962280209105015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Renfro LA, Shi Q, Xue Y, Li J, Shang H, Sargent DJ. Center-Within-Trial Versus Trial-Level Evaluation of Surrogate Endpoints. Comput Stat Data Anal 2014;78:1-20. [PMID: 25061255 DOI: 10.1016/j.csda.2014.03.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
2 Rath A, Salamon V, Peixoto S, Hivert V, Laville M, Segrestin B, Neugebauer EAM, Eikermann M, Bertele V, Garattini S, Wetterslev J, Banzi R, Jakobsen JC, Djurisic S, Kubiak C, Demotes-Mainard J, Gluud C. A systematic literature review of evidence-based clinical practice for rare diseases: what are the perceived and real barriers for improving the evidence and how can they be overcome? Trials 2017;18:556. [PMID: 29166947 DOI: 10.1186/s13063-017-2287-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
3 Flórez AJ, Molenberghs G, Van der Elst W, Alonso Abad A. An efficient algorithm to assess multivariate surrogate endpoints in a causal inference framework. Computational Statistics & Data Analysis 2022;172:107494. [DOI: 10.1016/j.csda.2022.107494] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Pozzi L, Schmidli H, Ohlssen DI. A Bayesian hierarchical surrogate outcome model for multiple sclerosis. Pharmaceut Statist 2016;15:341-8. [DOI: 10.1002/pst.1749] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
5 Plomgaard AM, van Oeveren W, Petersen TH, Alderliesten T, Austin T, van Bel F, Benders M, Claris O, Dempsey E, Franz A. The SafeBoosC II randomized trial: treatment guided by near-infrared spectroscopy reduces cerebral hypoxia without changing early biomarkers of brain injury. Pediatr Res. 2016;79:528-535. [PMID: 26679155 DOI: 10.1038/pr.2015.266] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 5.4] [Reference Citation Analysis]
6 Ivandic V. Requirements for benefit assessment in Germany and England - overview and comparison. Health Econ Rev 2014;4:12. [PMID: 26054401 DOI: 10.1186/s13561-014-0012-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
7 Boucher M, Bennetts M. The Many Flavors of Model-Based Meta-Analysis: Part I-Introduction and Landmark Data. CPT Pharmacometrics Syst Pharmacol 2016;5:54-64. [PMID: 26933516 DOI: 10.1002/psp4.12041] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
8 Van der Elst W, Molenberghs G, Alonso A. Exploring the relationship between the causal-inference and meta-analytic paradigms for the evaluation of surrogate endpoints. Stat Med 2016;35:1281-98. [PMID: 26612787 DOI: 10.1002/sim.6807] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
9 Flórez AJ, Molenberghs G, Verbeke G, Abad AA. A closed-form estimator for meta-analysis and surrogate markers evaluation. J Biopharm Stat 2019;29:318-32. [PMID: 30365364 DOI: 10.1080/10543406.2018.1535504] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]